mbiomics' €30M raise for microbiome cancer co-therapy signals a critical shift: it's not just about...

mbiomics' €30M raise for microbiome cancer co-therapy signals a critical shift: it's not just about new drugs, but enhancing existing immune response treatments.

For Indian pharma & biotech, this opens a huge frontier in precision oncology. We have the microbial diversity and research talent to lead in this space. Strategic R&D focus needed.

https://thenextweb.com/news/mbiomics-30m-series-a-microbiome-melanoma